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Abstract
Introduction: Epithelial ovarian cancer is one of the most common gynecological malignancies and
the fifth most frequent cause of cancer death in women, affecting over 22,000 women annually.
Nearly 15,500 affected women die from this disease annually, and chemoresistance from the
commonly prescribed platinum-based drug, carboplatin, is a major contributor to this mortality.
Previous studies have identified genes with CpG islands that are methylated and transcriptionally
silenced in resistant epithelial ovarian cancer patients. One of these genes is GSK3β, an important
regulator of apoptosis and cell growth in the Wnt pathway. Thus, understanding the role of GSK3β
suppression in chemoresistance of epithelial ovarian cancer can help contribute to more effective
treatments for this disease. By performing different assays our study examined the functional role
that GSK3β plays in carboplatin chemoresistance.
Procedure: Human ovarian surface epithelium (HOSE) 6-3 cell line was utilized, which is
characterized as sensitive to carboplatin therapy. The cells were studied in six groups: 1) untreated;
2) treated with Lithium Chloride (LiCl); 3) treated with carboplatin; 4) treated with carboplatin and
LiCl; 5) treated with doxorubicin as control; 6) treated with doxorubicin and LiCl as another control.
LiCl is known to suppress GSK3β gene expression. We took images of cells using a fluorescence
microscope. We also performed the Neutral Red Dye assay that determines cell viability, Vybrant®
MTT Cell Assay which measures amount of non-viable cells, Caspase 3 Assay which measures cell
apoptosis, and we did cell counting using a hemocytometer and a light microscope. Data analysis
was done by T-tests using Microsoft Excel®, with p < .05 for significance.
Summary of Data: More growth was observed in the carboplatin and LiCl group compared to the
carboplatin group alone on microscopy. Neutral Red Dye assay: Compared to the cells exposed to
carboplatin alone, those exposed to carboplatin and LiCl were more viable (p <0.01). Vybrant® MTT
Cell Assay: the cells treated with carboplatin and LiCl showed lesser amounts of nonviable cells as
compared to the carboplatin alone group (p<0.01). Caspase 3 Assay: the cells treated with
carboplatin and LiCl were less apoptotic, compared to cells treated with carboplatin alone (p <0.01).
Cell Counting: cells treated with carboplatin and LiCl had significantly more growth compared to the
cells treated with carboplatin alone (p <0.01).
Conclusion: Our results show that cells with suppressed GSK3β had increased proliferation and
reduced apoptosis, strongly suggesting that silenced GSK3β expression contributes to carboplatin
resistance and GSK3β expression is vital to carboplatin chemosensitivity. Future in vivo studies
could further investigate the role of GSK3β methylation to facilitate the design of potential genomeguided treatments for patients with chemoresistant epithelial ovarian cancer.

